Catherine J. Wu, MD

Catherine J. Wu, MD

Medical Oncology

Contact Information

Office Phone Number







Catherine J. Wu, MD

Dr. Wu received her MD from Stanford University School of Medicine in 1994. She completed postgraduate training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology and hematology at Dana-Farber/Partners CancerCare. In 2000, she joined Dana-Farber, where she currently leads the Division of Stem Cell Transplantation and Cellular Therapies. Her research interests include the identification of targets of the immune response associated with therapies and dissecting the basis of effective human antitumor responses.



Chief, Division of Stem Cell Transplantation and Cellular Therapies
Lavine Family Chair for Preventative Cancer Therapies
Professor of Medicine, Harvard Medical School


Stem Cell Transplantation

Clinical Interests

Acute myeloid leukemia, Chronic lymphoblastic leukemia, Chronic myeloid leukemia, Sickle cell anemia, Stem cell transplantation, Tumor antigens

Board Certification

  • Hematology, 2002
  • Internal Medicine, 1997
  • Medical Oncology, 2001


  • Dana-Farber/Partners CancerCare, Hematology & Oncology


  • Brigham and Women's Hospital, Internal Medicine

Medical School

  • Stanford University School of Medicine

Recent Awards

  • National Academy of Medicine, Member, 2019
  • Claire W. and Richard P. Morse Research Award, DFCI, 2017
  • The One Hundred, Massachusetts General Hospital Cancer Center, 2017
  • Medical Oncology Discovery Award, DFCI, 2015
  • American Society for Clinical Investigation, Member, 2012


    My ongoing research studies focus on how best to effectively mount human immune responses to recognize and eradicate cancer, with dedicated effort on the discovery and targeting of tumor antigens. A longstanding theme of my studies has been how best to launch immunotherapeutic efforts in a personalized fashion, initially through studies in the area of hematopoietic stem cell transplantation (HSCT) together with whole tumor cell vaccination and more recently through the implementation of personal neoantigen-targeting cancer vaccines (Ott & Hu Nature 2017; NCT 01970358). Key to our antigen discovery efforts has been our pioneering of approaches to leverage the recent availability of next-generation massively parallel sequencing technologies to perform comprehensive genomic dissection of leukemia cells. Our efforts have led to the discovery of key mutated genes and pathways involved in the pathogenesis of chronic lymphocytic leukemia (CLL) (N Engl J Med 2011), understanding of the vast clonal heterogeneity of leukemia samples and its impact on clonal evolution (Cell 2013), and the development of resistance to therapy (Nature 2015). We have further leveraged these sequencing technologies to pioneer computational tools for the comprehensive discovery of potential personal tumor-specific neoantigens. Neoantigens are a promising novel class of cancer targets created by the personal mutations found in each patient’s tumor which we have demonstrated in first-in-human trials for advanced melanoma and glioblastoma (Nature 2017, Nature 2019).  Because these mutations generate peptides that are distinct from “self”-peptides, the resulting epitopes are expected to escape the immune dampening effects of central tolerance.  As a physician-scientist with deep insight into how to bridge important basic discoveries with questions of high clinical relevance, I am committed to dedicating our efforts on the critical question of addressing the challenge of understanding the basis of disease progression and of therapeutic resistance in blood malignancies.

    Research Departments


      • Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia. Blood Adv. 2023 Oct 10; 7(19):5877-5889. View in: Pubmed

      • Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. Cancer Res. 2023 10 02; 83(19):3284-3304. View in: Pubmed

      • Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023 Sep 26. View in: Pubmed

      • Design of Cytotoxic T Cell Epitopes by Machine Learning of Human Degrons. bioRxiv. 2023 Sep 26. View in: Pubmed

      • ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 Sep 21. View in: Pubmed

      • Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing. STAR Protoc. 2023 Sep 18; 4(4):102165. View in: Pubmed

      • Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol. 2023 Sep 08; 8(87):eadf4968. View in: Pubmed

      • Author Correction: Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat Biotechnol. 2023 Sep; 41(9):1345. View in: Pubmed

      • SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation. J Clin Invest. 2023 09 01; 133(17). View in: Pubmed

      • Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood Adv. 2023 08 22; 7(16):4514-4517. View in: Pubmed

      • Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2023 Aug 29; 42(8):113011. View in: Pubmed

      • Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023 08 08; 7(15):3903-3915. View in: Pubmed

      • Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023 08 08; 7(15):4080-4088. View in: Pubmed

      • IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia. Blood Adv. 2023 Jul 28. View in: Pubmed

      • ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nat Cancer. 2023 07; 4(7):1016-1035. View in: Pubmed

      • Richter syndrome: novel insights into the biology of transformation. Blood. 2023 Jul 06; 142(1):11-22. View in: Pubmed

      • Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res. 2023 06 13; 29(12):2226-2238. View in: Pubmed

      • Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Adv. 2023 06 13; 7(11):2431-2435. View in: Pubmed

      • A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966. View in: Pubmed

      • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

      • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

      • Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023 05; 23(5):295-316. View in: Pubmed

      • Slide-tags: scalable, single-nucleus barcoding for multi-modal spatial genomics. bioRxiv. 2023 Apr 03. View in: Pubmed

      • Mitochondrial DNA Mutations as Natural Barcodes for Lineage Tracing of Murine Tumor Models. Cancer Res. 2023 03 02; 83(5):667-672. View in: Pubmed

      • Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). J Immunother Cancer. 2023 03; 11(3). View in: Pubmed

      • YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma. J Clin Invest. 2023 03 01; 133(5). View in: Pubmed

      • In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 03 01; 4(2):150-169. View in: Pubmed

      • Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci Immunol. 2023 02 03; 8(80):eabm6359. View in: Pubmed

      • Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun. 2023 01 31; 14(1):506. View in: Pubmed

      • The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. Blood. 2023 01 26; 141(4):369-379. View in: Pubmed

      • The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv. 2023 01 10; 7(1):145-158. View in: Pubmed

      • Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169. View in: Pubmed

      • Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 11 24; 140(21):2193-2227. View in: Pubmed

      • Vaccination with designed neopeptides induces intratumoral, cross-reactive CD4+ T cell responses in glioblastoma. Clin Cancer Res. 2022 Oct 13. View in: Pubmed

      • Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022 10 11; 55(10):1940-1952.e5. View in: Pubmed

      • Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. Sci Adv. 2022 Sep 16; 8(37):eabq5089. View in: Pubmed

      • AML relapse after a TIGIT race. Blood. 2022 09 15; 140(11):1189-1191. View in: Pubmed

      • Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 09 15; 28(18):4045-4055. View in: Pubmed

      • Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022 09; 28(9):1848-1859. View in: Pubmed

      • Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 11; 54(11):1664-1674. View in: Pubmed

      • Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366. View in: Pubmed

      • Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2204078119. View in: Pubmed

      • Cancer vaccines: Building a bridge over troubled waters. Cell. 2022 07 21; 185(15):2770-2788. View in: Pubmed

      • Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413. View in: Pubmed

      • Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J Clin Invest. 2022 07 01; 132(13). View in: Pubmed

      • Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505. View in: Pubmed

      • Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed

      • Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. Front Immunol. 2022; 13:859032. View in: Pubmed

      • Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022 05; 605(7910):532-538. View in: Pubmed

      • Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 09 01; 40(25):2913-2923. View in: Pubmed

      • Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines. Curr Opin Immunol. 2022 06; 76:102176. View in: Pubmed

      • GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194. View in: Pubmed

      • Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 04 07; 139(14):2252-2256. View in: Pubmed

      • cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nat Commun. 2022 03 31; 13(1):1698. View in: Pubmed

      • Tumor-Infiltrating T Cells - A Portrait. N Engl J Med. 2022 Mar 10; 386(10):992-994. View in: Pubmed

      • Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689. View in: Pubmed

      • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291. View in: Pubmed

      • Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190. View in: Pubmed

      • Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics. Front Immunol. 2021; 12:788891. View in: Pubmed

      • Understanding CLL biology through mouse models of human genetics. Blood. 2021 12 23; 138(25):2621-2631. View in: Pubmed

      • Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. Front Oncol. 2021; 11:790004. View in: Pubmed

      • Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. View in: Pubmed

      • Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063. View in: Pubmed

      • Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021 11 23; 5(22):4701-4709. View in: Pubmed

      • Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992. View in: Pubmed

      • Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130. View in: Pubmed

      • Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022 02; 40(2):209-217. View in: Pubmed

      • Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat Commun. 2021 09 13; 12(1):5395. View in: Pubmed

      • Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Mol Cell Proteomics. 2021; 20:100133. View in: Pubmed

      • Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986. View in: Pubmed

      • Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125. View in: Pubmed

      • Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clin Cancer Res. 2021 09 15; 27(18):5062-5071. View in: Pubmed

      • Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clin Cancer Res. 2021 09 15; 27(18):5072-5083. View in: Pubmed

      • Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Cancer. 2021 07; 2(7):758-772. View in: Pubmed

      • Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217. View in: Pubmed

      • 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Res. 2021 09 01; 81(17):4373-4384. View in: Pubmed

      • Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discov. 2021 09; 11(9):2266-2281. View in: Pubmed

      • Splice it up: Atypical transcripts to boost leukemia immunotherapy. Immunity. 2021 04 13; 54(4):608-610. View in: Pubmed

      • Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8. View in: Pubmed

      • A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8. View in: Pubmed

      • Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581). View in: Pubmed

      • COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871. View in: Pubmed

      • Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808. View in: Pubmed

      • Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364. View in: Pubmed

      • Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525. View in: Pubmed

      • Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 04; 18(4):199-214. View in: Pubmed

      • Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98. View in: Pubmed

      • Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 09 15; 27(18):5038-5048. View in: Pubmed

      • Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System. Mol Cancer Res. 2021 04; 19(4):623-635. View in: Pubmed

      • Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discov. 2021 01; 2(1):13-18. View in: Pubmed

      • Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discov. 2021 01; 2(1):13-18. View in: Pubmed

      • Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 09 15; 27(18):5049-5061. View in: Pubmed

      • Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69. View in: Pubmed

      • Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020 12; 8(12):1465-1469. View in: Pubmed

      • Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380. View in: Pubmed

      • Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47. View in: Pubmed

      • High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biol. 2020 10 20; 21(1):266. View in: Pubmed

      • Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). View in: Pubmed

      • Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123. View in: Pubmed

      • Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Res. 2020 11 01; 80(21):4854-4867. View in: Pubmed

      • Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat Biotechnol. 2021 04; 39(4):451-461. View in: Pubmed

      • Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307. View in: Pubmed

      • Delineating the evolutionary dynamics of cancer from theory to reality. Nat Cancer. 2020 06; 1(6):580-588. View in: Pubmed

      • A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191. View in: Pubmed

      • Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918. View in: Pubmed

      • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802. View in: Pubmed

      • Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. J Clin Invest. 2020 04 01; 130(4):1595-1607. View in: Pubmed

      • Measuring the predictability of life outcomes with a scientific mass collaboration. Proc Natl Acad Sci U S A. 2020 04 14; 117(15):8398-8403. View in: Pubmed

      • Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat Commun. 2020 03 18; 11(1):1438. View in: Pubmed

      • Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020 02; 10(2):185-197. View in: Pubmed

      • CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020 06; 34(6):1599-1612. View in: Pubmed

      • Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723. View in: Pubmed

      • A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020 02; 38(2):199-209. View in: Pubmed

      • Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res. 2020 03 15; 26(6):1359-1371. View in: Pubmed

      • Clonal dynamics in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):466-475. View in: Pubmed

      • Clonal dynamics in chronic lymphocytic leukemia. Blood Adv. 2019 11 26; 3(22):3759-3769. View in: Pubmed

      • Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019 Nov 01; 5(11):1631-1633. View in: Pubmed

      • Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13. View in: Pubmed

      • Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020 05; 105(5):1379-1390. View in: Pubmed

      • RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat Protoc. 2019 08; 14(8):2571-2594. View in: Pubmed

      • SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496. View in: Pubmed

      • Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479. View in: Pubmed

      • Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019 05; 569(7757):576-580. View in: Pubmed

      • Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2019 Aug; 30(8):799-811. View in: Pubmed

      • Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat Commun. 2019 04 23; 10(1):1874. View in: Pubmed

      • Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019 09; 33(9):2183-2194. View in: Pubmed

      • Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019 04; 9(4):476-481. View in: Pubmed

      • Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. Am J Hematol. 2019 04; 94(4):446-454. View in: Pubmed

      • Dissecting CLL through high-dimensional single-cell technologies. Blood. 2019 03 28; 133(13):1446-1456. View in: Pubmed

      • A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5. View in: Pubmed

      • irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184. View in: Pubmed

      • Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. View in: Pubmed

      • A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432. View in: Pubmed

      • Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018 11 22; 10(1):87. View in: Pubmed

      • Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). View in: Pubmed

      • A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921. View in: Pubmed

      • Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033. View in: Pubmed

      • Immunotherapy for glioblastoma: going viral. Nat Med. 2018 08; 24(8):1094-1096. View in: Pubmed

      • DeTiN: overcoming tumor-in-normal contamination. Nat Methods. 2018 07; 15(7):531-534. View in: Pubmed

      • Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8. View in: Pubmed

      • TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018; 7(7):e1442999. View in: Pubmed

      • Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. View in: Pubmed

      • Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 2018 06; 8(6):730-749. View in: Pubmed

      • The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185. View in: Pubmed

      • Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 03; 18(3):168-182. View in: Pubmed

      • SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell. 2017 11 13; 32(5):716-716.e1. View in: Pubmed

      • Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25. View in: Pubmed

      • High-dimension single-cell analysis applied to cancer. Mol Aspects Med. 2018 02; 59:70-84. View in: Pubmed

      • HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017 07 10; 32(1):1-3. View in: Pubmed

      • An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221. View in: Pubmed

      • Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311. View in: Pubmed

      • Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med. 2017 Apr 03; 7(4). View in: Pubmed

      • Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J. 2017 Mar/Apr; 23(2):115-124. View in: Pubmed

      • Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity. 2017 02 21; 46(2):315-326. View in: Pubmed

      • Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204. View in: Pubmed

      • Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493. View in: Pubmed

      • Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 Mar 20; 35(9):984-993. View in: Pubmed

      • Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008. View in: Pubmed

      • Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096. View in: Pubmed

      • Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep. 2017 Feb; 19:42-45. View in: Pubmed

      • Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763. View in: Pubmed

      • Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206. View in: Pubmed

      • Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417. View in: Pubmed

      • Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. View in: Pubmed

      • Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat Genet. 2016 07; 48(7):725-32. View in: Pubmed

      • Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. View in: Pubmed

      • Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16. View in: Pubmed

      • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98. View in: Pubmed

      • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25; 351(6280):1463-9. View in: Pubmed

      • Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clin Cancer Res. 2016 Apr 01; 22(7):1547-9. View in: Pubmed

      • Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23. View in: Pubmed

      • Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015 Nov; 33(11):1152-8. View in: Pubmed

      • Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22; 526(7574):525-30. View in: Pubmed

      • Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 09; 350(6257):207-211. View in: Pubmed

      • Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015 Jul 23; 126(4):445-53. View in: Pubmed

      • The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. View in: Pubmed

      • Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015 Apr; 15(4):201-15. View in: Pubmed

      • Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15; 160(1-2):48-61. View in: Pubmed

      • Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825. View in: Pubmed

      • Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. J Clin Invest. 2014 Nov; 124(11):4681-3. View in: Pubmed

      • Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58. View in: Pubmed

      • Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3:e29311. View in: Pubmed

      • Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62. View in: Pubmed

      • Evolving understanding of the CLL genome. Semin Hematol. 2014 Jul; 51(3):177-87. View in: Pubmed

      • Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98. View in: Pubmed

      • Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69. View in: Pubmed

      • Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology. 2014; 3:e28187. View in: Pubmed

      • HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9. View in: Pubmed

      • Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21. View in: Pubmed

      • Boosting leukemia-specific T cell responses in patients following stem cell transplantation. Oncoimmunology. 2013 Nov 01; 2(11):e26587. View in: Pubmed

      • Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45. View in: Pubmed

      • Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65. View in: Pubmed

      • Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218. View in: Pubmed

      • An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615. View in: Pubmed

      • Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013; 5(5):47. View in: Pubmed

      • SF3B1 mutations in chronic lymphocytic leukemia. Blood. 2013 Jun 06; 121(23):4627-34. View in: Pubmed

      • Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013 Jul; 1(1):11-5. View in: Pubmed

      • Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26. View in: Pubmed

      • An overview of the BioCreative 2012 Workshop Track III: interactive text mining task. Database (Oxford). 2013; 2013:bas056. View in: Pubmed

      • BioCreative-2012 virtual issue. Database (Oxford). 2012; 2012:bas049. View in: Pubmed

      • The eFIP system for text mining of protein interaction networks of phosphorylated proteins. Database (Oxford). 2012; 2012:bas044. View in: Pubmed

      • Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504. View in: Pubmed

      • CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012 Nov 15; 120(20):4117-8. View in: Pubmed

      • Recent advances in biocuration: meeting report from the Fifth International Biocuration Conference. Database (Oxford). 2012; 2012:bas036. View in: Pubmed

      • Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103. View in: Pubmed

      • Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9. View in: Pubmed

      • CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 Feb; 62(2):347-57. View in: Pubmed

      • Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72. View in: Pubmed

      • Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802. View in: Pubmed

      • Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: Pubmed

      • Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines. Front Biosci (Landmark Ed). 2012 01 01; 17(2):635-55. View in: Pubmed

      • Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S151-60. View in: Pubmed

      • SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506. View in: Pubmed

      • Components of the hematopoietic compartments in tumor stroma and tumor-bearing mice. PLoS One. 2011 Mar 25; 6(3):e18054. View in: Pubmed

      • Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84. View in: Pubmed

      • Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother. 2011 Jun; 60(6):857-67. View in: Pubmed

      • Data processing and analysis for protein microarrays. Methods Mol Biol. 2011; 723:337-47. View in: Pubmed

      • In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011 Jan; 96(1):13-5. View in: Pubmed

      • A coprecipitation-based validation methodology for interactions identified using protein microarrays. Methods Mol Biol. 2011; 723:239-54. View in: Pubmed

      • Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8. View in: Pubmed

      • Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39. View in: Pubmed

      • Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010 May 27; 115(21):4206-16. View in: Pubmed

      • Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51. View in: Pubmed

      • Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55. View in: Pubmed

      • Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15. View in: Pubmed

      • Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res. 2009 Aug 15; 69(16):6546-55. View in: Pubmed

      • Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res. 2009 Jul 15; 15(14):4515-7. View in: Pubmed

      • Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1270-8. View in: Pubmed

      • Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15. View in: Pubmed

      • A concentration-dependent analysis method for high density protein microarrays. J Proteome Res. 2008 May; 7(5):2059-68. View in: Pubmed

      • Allogeneic stem cell transplantation for the treatment of hemoglobinopathies. Stem Cell Transplantation for Hematologic Malignancies. 2008. View in: Pubmed

      • Immunologic targeting of the cancer stem cell. The Stem Book. 2008. View in: Pubmed

      • Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7. View in: Pubmed

      • Integration of bioinformatics resources for functional analysis of gene expression and proteomic data. Front Biosci. 2007 Sep 01; 12:5071-88. View in: Pubmed

      • Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82. View in: Pubmed

      • Proteome informatics for cancer research: from molecules to clinic. Proteomics. 2007 Mar; 7(6):976-91. View in: Pubmed

      • Target discovery using proteomic microarrays. BIOforum Europe. 2007; 11(10):20-22. View in: Pubmed

      • Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006; 90:133-73. View in: Pubmed

      • Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45. View in: Pubmed

      • Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11. View in: Pubmed

      • Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50. View in: Pubmed

      • Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8. View in: Pubmed

      • Inflammatory myopathy associated with imatinib mesylate therapy. J Clin Neuromuscul Dis. 2004 Mar; 5(3):119-21. View in: Pubmed

      • Antibody response to BCMA in patients with multiple myeloma. 12th International Congress of Immunology and 4th Annual Conference of FOCIS. 2004; 355-63. View in: Pubmed

      • A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol. 2004 Jan 01; 172(1):651-60. View in: Pubmed

      • Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63. View in: Pubmed

      • Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct; 31(10):924-33. View in: Pubmed

      • Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5. View in: Pubmed

      • Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9. View in: Pubmed

      • CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522. View in: Pubmed

      • Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7. View in: Pubmed

      • Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32. View in: Pubmed

      • Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21. View in: Pubmed

      • CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7. View in: Pubmed

      • A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7. View in: Pubmed

      • The immunocompromised host. Samter's Immunologic Diseases,. 2001; 81:1067-1085. View in: Pubmed

      • Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14. View in: Pubmed

      • Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9. View in: Pubmed

      • Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5. View in: Pubmed

      • Cytokine gene expression in human cardiac allograft recipients. Transpl Immunol. 1994 Sep; 2(3):199-207. View in: Pubmed

      • Cytokine gene expression in human lung transplant recipients. Transplantation. 1993 Oct; 56(4):956-61. View in: Pubmed

      • Cytokine gene expression in rejecting cardiac allografts. Transplantation. 1992 Aug; 54(2):326-32. View in: Pubmed

      • Murine memory B cells are multi-isotype expressors. Immunology. 1991 Jan; 72(1):48-55. View in: Pubmed


      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 520C Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Dana 520C Boston, MA 02215
      Get Direction
      42.3374, -71.1082